HEFT Repository

Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies.

Taylor, Stephen and Jayasuriya, Ashini and Fisher, Martin and Allan, Sris and Wilkins, Ed and Gilleran, Gerry and Heald, Lisa and Fidler, Sarah and Owen, Andrew and Back, David and Smit, Erasmus (2012) Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. The Journal of antimicrobial chemotherapy, 67 (3). pp. 675-80. ISSN 1460-2091.

Full text not available from this repository. (Request a copy)
Official URL: http://jac.oxfordjournals.org/content/67/3/675.lon...

Abstract

Plasma efavirenz concentrations can persist up to 3 weeks after patients stop efavirenz-containing regimens. This suggests a strategy of stopping efavirenz only 1 week before NRTIs may not be long enough for some individuals. The use of lopinavir/ritonavir monotherapy for a 4 week period may be an alternative pharmacologically and virologically effective universal stopping strategy which warrants further investigation.

Item Type: Article
Subjects: WC Communicabable diseases
Divisions: Clinical Support > Infectious Diseases
Depositing User: Sophie Rollason
Date Deposited: 10 Jun 2014 13:42
Last Modified: 10 Jun 2014 13:42
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/126

Actions (login required)

View Item View Item